Literature DB >> 10703606

Presence of the DRB4*0103102N null allele in different DRB1*04-positive individuals.

C E Voorter1, N M Lardy, E M van den Berg-Loonen.   

Abstract

The DRB4 gene encoding the DR53 antigen is present in DRB1*04-, DRB1*07- and DRB1*09-positive individuals. Eight allelic variants of DRB4 have been recognized, 5 resulting in an expressed DR53 antigen and 3 belonging to the null alleles. So far the DRB4*0103102N null allele had been found exclusively in individuals carrying the haplotype DR7,-DQ9. High-resolution typing of HLA class II by polymerase chain reaction using sequence-specific primers (PCR-SSP) and/or sequence-based typing of kidney patients and their families revealed the presence of the DRB4*0103102N null allele segregating with DRB1*04 and DQB1*03 in 4 different families. Three different haplotypes on which the null allele was located, were recognized by family studies: DRB1*0401, DQB1*0301; DRB1*0402, DQB1*0302 and DRB1*0404, DQB1*0302. Determination of the DR53 specificity of antisera reacting with DR53-positive individuals has always been difficult due to the simultaneous presence of DR4, 7 or 9. Identification of DR4-positive DR53-negative individuals as described here, provided the serological reactions with DR53-antisera and revealed the antibody specificities in the antisera used.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703606     DOI: 10.1034/j.1399-0039.2000.550106.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  2 in total

1.  HLA-DR53 (DRB4∗01) associates with nickel sensitization.

Authors:  Yan Zhang; Kirsten M Anderson; Brian M Freed; Shaodong Dai; Karin A Pacheco
Journal:  Ann Allergy Asthma Immunol       Date:  2020-07-18       Impact factor: 6.347

2.  Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome.

Authors:  Saghar Kaabinejadian; Carolina Barra; Bruno Alvarez; Hooman Yari; William H Hildebrand; Morten Nielsen
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.